Company intelligence / Profile preview
Actithera
Cambridge, Massachusetts, United Statesactithera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Actithera has developed a proprietary radiotherapeutic platform that links radioactive isotopes to small molecule or peptide carriers designed for rapid, specific, and persistent delivery into tumors while sparing healthy tissue. Their lead program targets FAP with preclinical data showing superior tumor uptake/retention compared to benchmarks. The company aims to bring its first program through IND-enabling studies toward Phase I/II proof-of-concept trials by late 2025 or beyond.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesPeptidesRadiotherapeutics (radioactive isotopes linked to targeting molecules)Theranostics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Exclusive option agreement to in-license complementary technology; four academic collaborations signed as of early/mid 2025.
Beyond the preview
Go deeper on Actithera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actithera.